Short Interest in Akili, Inc. (NASDAQ:AKLI) Drops By 56.5%

Akili, Inc. (NASDAQ:AKLI) saw a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 271,400 shares, a decrease of 56.5% from the May 31st total of 623,800 shares. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.7% of the shares of the stock are sold short.

Akili Price Performance

Shares of NASDAQ:AKLI opened at $0.43 on Friday. The stock’s 50 day moving average price is $0.40 and its 200 day moving average price is $0.35. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.80 and a quick ratio of 5.80. The stock has a market cap of $34.22 million, a price-to-earnings ratio of -0.71 and a beta of 1.71. Akili has a 12 month low of $0.19 and a 12 month high of $1.25.

Akili (NASDAQ:AKLI) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.13) earnings per share for the quarter. The firm had revenue of $0.38 million during the quarter. Akili had a negative net margin of 2,492.04% and a negative return on equity of 79.93%. Equities research analysts anticipate that Akili will post -0.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Akili

An institutional investor recently bought a new position in Akili stock. StoneX Group Inc. bought a new position in shares of Akili, Inc. (NASDAQ:AKLI) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,064,432 shares of the company’s stock, valued at approximately $518,000. StoneX Group Inc. owned approximately 1.36% of Akili as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 53.12% of the company’s stock.

About Akili

Akili, Inc, a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.